Recent

% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

  • danq_94118 danq_94118 Feb 2, 2012 3:31 PM Flag

    A Buyout could value AMLN @ $32/sh

    .....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • who said they will sell out for 32?

    • more than that

    • Analyst Sees Increased Chance of Amylin (AMLN) Takeover Amid Bydureon Approval



      FREE Breaking News Alerts from StreetInsider.com!

      E-mail Address

      More News related to AMLN
      Notable 52-Week Highs and Lows of the Day 02/02: (AMLN) (QCOM) (CDNS) High; (ANF) (CMED) (CMRG) Low
      Stocks with implied volatility movement; AMLN BTU
      Amylin Pharmaceuticals to Webcast 2011 Year-End Financial Results
      Analyst Sees Increased Chance of Amylin (AMLN) Takeover Amid Bydureon Approval
      Unusual 11 Midday Movers 01/30: (GTXI) (ONCY) (PBY) Higher; (CTIC) (EMKR) (PMC) Lower
      More News related to AMLN

      More News related to Analyst Comments
      Shares of Allegiant Travel (ALGT) Take Breather After Six-Month Climb
      Shares of Tractor Supply (TSCO) Fall After Q4 Report; Wall Street Firms Remain Positive
      Barclays Maintains an 'Overweight' on Shutterfly (SFLY); Cutting Numbers as Guidance Reflects Growing Competition
      Jefferies Maintains a 'Hold' on Autoliv, Inc. (ALV); Follow-Up to Q4 Results
      Baird Chimes In on Zynga (ZNGA) After Facebook Boost
      More News related to Analyst Comments
      January 30, 2012 2:52 PM EST
      Piper Jaffray's Ian Somaiya issued a note Monday morning suggesting FDA approval of Bydureon increases chances for a takeover of Amylin (Nasdaq: AMLN).

      Somaiya believes Amylin could be worth $33 per share based on an average multiple; applying a historic multiple which assumes peak sales gets the value into the $37-$49 per share range.

      Piper Jaffray maintains an Overweight rating and $17 price target on shares of Amylin